STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir’s (STO:MVIRB) phase III project Lipsovir® has now enrolled and issued study drug to all of the intended patients. In two of the studies, the final patient has commenced treatment.
The phase III program consists of three studies. The first study, which enrolled children and adolescents, commenced in January 2007 and is being performed in Sweden and Russia. The aim of the study is to confirm the safety profile of Lipsovir® in this age group. The study embraces 240 patients, of which 130 are to be treated with Lipsovir®. The final patient has now started treatment, which is ahead of schedule.
